Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Medivir AB ( (SE:MVIR) ) is now available.
Medivir AB announced a live Business Update at Redeye, where CEO Jens Lindberg will discuss a new Right’s Issue to fund a study comparing their drug candidate fostrox combined with lenvatinib against lenvatinib alone for second-line liver cancer treatment. This initiative highlights Medivir’s commitment to enhancing cancer treatment options and could strengthen its position in the pharmaceutical industry by addressing significant unmet medical needs.
The most recent analyst rating on (SE:MVIR) stock is a Buy with a SEK54.00 price target. To see the full list of analyst forecasts on Medivir AB stock, see the SE:MVIR Stock Forecast page.
More about Medivir AB
Medivir AB is a pharmaceutical company listed on Nasdaq Stockholm, focusing on developing innovative cancer treatments, particularly in areas with high unmet medical needs. The company is dedicated to advancing drug candidates like fostroxacitabine bralpamide (fostrox) aimed at treating liver cancer with minimal side effects. Medivir emphasizes collaborations and partnerships in its business model.
Average Trading Volume: 660,191
Technical Sentiment Signal: Sell
Current Market Cap: SEK50.69M
See more insights into MVIR stock on TipRanks’ Stock Analysis page.